on 21 Feb 2023
Last Applicant/ Owned by
Sydmarken 11
Søborg
DK
2860
Serial Number
90144485 filed on 28th Aug 2020
Registration Number
6986947 registered on 21st Feb 2023
Correspondent Address
Shannon Marie McKeon
Filing Basis
1. intent to use
2. use application currently
Disclaimer
"ZEALAND PHARMA"
(Based on Use in Commerce) Publication of articles and scientific text and posters featuring the results of clinical trials for pharmaceutical preparations related to diabetes, obesity and gastrointestinal diseases; providing educational seminars, educational exhibitions, conferences and training courses, all in the field of diabetes, obesity and gastrointestinal diseases; educational seminars, edRead More
(Based on 44(e)) Pharmaceutical preparations for the treatment of diabetes, obesity and gastrointestinal diseases; synthetic peptides for pharmaceuticals purposes for the treatment of diabetes, obesity and gastrointestinal diseases; pharmaceutical preparations for the treatment of diseases, illnesses and ailments in humans, namely, pharmaceutical preparations for treating endocrine disorders, immunity disorders, nutritional and metabolic diseases, such as diabetes and obesity; pharmaceutical preparations for the treatment and prevention of hypoglycemia; hypoglycemic agents; medical preparations in the nature of a liquid solution for medical purposes for the treatment and prevention of hypoglycemia; pharmaceutical preparations for treating gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; pharmaceutical preparations altering the immune system, such as complement inhibitors; apparatus and instruments containing pharmaceutical preparations, substances and medicines; medical rescue injection pens containing glucagon to treat severe cases of low blood sugar; pre-filled syringes for medical purposes containing insulin or glucagon or analogues of those
(Based on Use in Commerce) Medical apparatus and instruments, namely, diabetes management devices, infusion and injection devices, infusion pumps, infusion pump controllers and parts and attachments thereof; medical devices and sensors used to continuously monitor the concentration of glucose in the human body; blood glucose monitors for medical purposes; glucose monitor accessories, namely, transmitters, receivers, and medical sensor insertion devices; wearable medical devices for insulin monitoring; infusion pumps for improvement of glycemic control and auto-injector pens for the treatment of hypoglycemia; medical rescue injection pens for administrating glucagon; parts and accessories for all the aforesaid goods; wearable health devices for insulin monitoring
31st May 2021
31st May 2021
(Based on Use in Commerce) printed pharmaceutical information leaflets in the field of diabetes, obesity and gastrointestinal diseases; printed publications, namely, books, magazines, periodicals and manuals, all in the field of diabetes, obesity and gastrointestinal diseases; printed instructional or teaching matter in the field of diabetes, obesity and gastrointestinal diseases; printed instructional and teaching materials about diagnosing and treatment of diabetes, obesity and gastrointestinal diseases; printed guidelines for diagnosing and treatment of diabetes, obesity and gastrointestinal diseases
31st May 2021
31st May 2021
(Based on 44(e)) Marketing services; customer relationship management; business administrative services for medical referrals; patient relationship management services; business administration of pharmacy and pharmaceutical benefit plans
(Based on Use in Commerce) Publication of articles and scientific text and posters featuring the results of clinical trials for pharmaceutical preparations related to diabetes, obesity and gastrointestinal diseases; providing educational seminars, educational exhibitions, conferences and training courses, all in the field of diabetes, obesity and gastrointestinal diseases; educational seminars, educational exhibitions, conferences and instructional services relating to medical treatments in the field of diabetes, obesity and gastrointestinal diseases; educational services, namely, organizing and conducting educational programs, coaching and training services for patients and healthcare professionals related to management of diabetes, obesity and gastrointestinal diseases
31st May 2021
31st May 2021
(Based on 44(e)) Scientific and technological services, namely, research and design in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; industrial analysis and research services in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; medical, biological, biotechnological, genetic, laboratory and pharmaceutical research, design and development services; laboratory research in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; information and consultancy services relating to all the aforesaid; providing scientific information on diabetes, obesity and gastrointestinal diseases; providing websites featuring technology that enables users to record, track, and generate reports regarding the condition, treatment and the management of diabetes, obesity and gastrointestinal diseases; computer services, namely, providing a website featuring technology that enables users to obtain data concerning medical analysis and management of diabetes, obesity and gastrointestinal diseases
(Based on 44(e)) Medical analysis services for the diagnosis and treatment of humans; medical consulting services in the field of diseases, illnesses and ailments in humans; medical services related to the testing and treatment of patients with diabetes or low blood sugar (hypoglycemia); medical services related to testing and treatment of patients with gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; clinical trials; medical consulting services, namely, providing patient adherence programs to patients suffering from diabetes, obesity or gastrointestinal diseases; providing web-based on-line portals that provide a patient adherence program to patients suffering from diabetes, obesity or gastrointestinal diseases; medical information services, namely, providing information relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical advisory services, namely, providing advisory services relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical services in the nature of patient support relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical information and advice in relation to treatment planning, including information and advice provided via the Internet, databases and application software; consultancy services relating to the aforesaid
(Based on 44(e)) Licensing of patent and intellectual property rights arising from medical and pharmaceutical research and development activities; licensing of proprietary intellectual property
No 90144485
No Service Mark
No 066369.0047
No
No
No
No
No
No
No
No
26.01.11 -
Letters, numerals, punctuation, geometric figures, objects, humans, plants or animals comprising a circle
26.01.16 -
Circles touching or intersecting
26.01.31 -
Five or more circles
The mark consists of the wording "ZEAL&" with each letter appearing in white, in a blue circle, an overlapped grey circle, an overlapped yellow circle, an overlapped turquoise circle, a red circle, from left to right, with the grey wording "ZEALAND PHARMA" written below.
| Status Date | Action Taken |
|---|---|
| 21st Feb 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| 21st Feb 2023 | REGISTERED-PRINCIPAL REGISTER |
| 14th Jan 2023 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| 13th Jan 2023 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| 17th Dec 2022 | ASSIGNED TO EXAMINER |
| 15th Nov 2022 | STATEMENT OF USE PROCESSING COMPLETE |
| 15th Nov 2022 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| 27th Oct 2022 | USE AMENDMENT FILED |
| 27th Oct 2022 | TEAS STATEMENT OF USE RECEIVED |
| 23rd Jun 2022 | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY |
